References
- Wu J. Expression of monoclonal-defined tumor markers in four carcinomas. Ann Clin Lab Sci 1989; 19: 17–26
- Hilkens J, Buijs F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van der Valk M. Monoclonal antibodies against human milk fat globule memebranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984; 34: 197–206
- Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223–32
- Stä hli C, Caravatti M, Aeschbacher M, Kocyba C, Takacs B, Carmann H. A mucin-like carcinoma associated-antigen defined by three monoclonal antibodies against different epitopes. Cancer Res 1988; 48: 6799–802
- Sacks N, Stacker J, Thompson C. Comparison of mammary serum antigen (MSA) and CA 15–3 levels in serum of patients with breast cancer. Br J Cancer 1987; 56: 820–4
- Beveridge R A, Chan D W, Bruzek D, et al. A new biomarker in monitoring breast cancer: CA 549. J Clin Oncol 1988; 6: 1815–21
- Linsley P S, Brown J P, Magnani J L, Horn D. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res 1988; 48: 2138–48
- McKenzie I, Xing P-X. Mucins in breast cancer recent immunological advances. Cancer Cells 1990; 2: 75–78
- Gendler SJ, Burchell J M, Duhig T, Lamport D, White R, Parker M, Taylor PJ. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 1987; 84: 6060–4
- Burchell J, Gendler S, Taylor P J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47: 5476–82
- Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989; 64: 1674–81
- Kallioniemi O P, Oksa H, Aaran R K, Hietanen T, Lehtinen M, Koivula T. Clinical utility of the combined use of plurime tumor markers in human breast cancer. Br J Cancer 1988; 58: 213–5
- Gozdz S S, Kowalska M M, Sluszniak J T, et al. Pretreaunent concentrations of breast carcinoma antigen (CA 15.3) and mucin-like carcinoma-associated antigen in patients with carcinoma of the breast. Tumour Biol 1989; 10: 103–8
- Steger G G, Mader R, Derfler K, Moser K, Dittrich C. Mucin-like cancer-associated antigen (MCA) compared with CA 15–3 in advanced breast cancer. Klin Wochenschr 1989; 67: 813–7
- Dniestrian A, Schwartz M, Greenberg E, Smith C, Schwartz D. Evaluation of CA M26, CA M29, CA 15–3 and CEA as circulating tumor markers for breast cancer patients. Tumor Biol 1991; 12: 82–90
- Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunologic adsorption techniques. 1965; 121: 139–62
- Laurence D, Jr, Stevens U, Bettelheim R, et al. Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma. Br J Med 1972; 1972: 605–9
- Gion M, Mione R, Gatti C, et al. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma?. Comparison with CA 15.3 and MCA. Tumori 1990; 76: 360–4
- Williams M, Turkes A, Pearson D, Griffiths K, Blarney R. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of data. Br J Cancer 1990; 61: 126–32
- Stenman U-H, Alfthan H, Tuipeinen U. Method dependence of interpretation of immunoassay results. Scand J Clin Lab Invest 1991; 51: 86–94, Suppl 205
- Kiang D T, Greenberg L J, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193–9
- Beard D, Haskell C. Carcinoembryonic antigen in breast cancer. Amer J Med 1986; 80: 241–5